Eloralintide: an investigational amylin analog, from its published studies

What is eloralintide, and what are people searching for?

Eloralintide, coded LY3841136, is a long-acting, selective agonist of the amylin receptor developed for once-weekly subcutaneous injection [2][3]. Amylin is a hormone released with insulin that slows stomach emptying and signals fullness [3]. Eloralintide is investigational: it is in clinical development and has no approved label anywhere.

A search for the name raises three questions: what it is, how it compares with GLP-1 medicines, and what amounts were used in studies. The last question has a published answer for research participants, reported below. It does not translate into a personal schedule, and because PinPoint's library does not list eloralintide, no half-life input or package example exists here to convert [4].

What do the eloralintide studies report?

A 2025 discovery paper traced eloralintide from its chemistry to early clinical proof of concept [3]. The phase 1 multiple ascending dose study, published in 2026, gave 100 participants with obesity or overweight weekly injections for 12 weeks without escalation. Exposure rose in proportion to dose, the most common adverse events were decreased appetite, headache and fatigue, and gastrointestinal events were infrequent. Mean weight reduction at 12 weeks ranged from 2.6% to 11.3% across dose groups [2].

The 48-week phase 2 study randomised 263 adults without type 2 diabetes to weekly placebo or eloralintide at 1, 3, 6 or 9 mg, or to escalation from 6 to 9 mg or from 3 to 9 mg [1]. Mean body-weight change ranged from 9% lower at 1 mg to 20% lower at 9 mg and with 6 to 9 mg escalation, against 0.4% lower on placebo. Nausea and fatigue were the most common adverse events and varied widely by arm [1].

These are research results in selected adults under monitoring, funded by the developer. They do not establish a label dose, and the figure in this section is a picture of reported group means, not an expected outcome for anyone.

How would eloralintide be measured and converted to units?

Arithmetic needs a presentation: a vial total, a solution concentration or a pen strength. Eloralintide has none, because it has no approved product and PinPoint's library holds no entry for it [4]. Any page that converts eloralintide milligrams into syringe units is assuming a concentration that no source in this guide supplies.

The general rule still applies to any product that does have a stated concentration: amount divided by concentration gives volume, and millilitres times 100 gives U-100 units [5]. The peptide calculator performs that step from values printed on a label. The closest compound in the library is cagrilintide, another investigational amylin analogue, whose guide shows the same arithmetic on a documented package example.

How do people track an investigational weekly injection in PinPoint?

PinPoint logs entries for compounds in its library, which covers amylin-related and GLP-1 compounds such as cagrilintide, semaglutide, tirzepatide and retatrutide [6][4]. For those, a weekly schedule with reminders on the chosen day and time, titration phases for planned step-ups, and a log of compound, dose, site and pain level are available [6].

Side effects with severity ratings and daily notes can be recorded alongside the dose history, and data can be exported as PDF, CSV or JSON [6]. Ask PinPoint can summarise what published references say about a compound, and it never recommends a dose or a change [6]. If eloralintide reaches a label, its prescribing information would supply the presentation, concentration and half-life that this page cannot.

What do people ask about eloralintide?

What is eloralintide?

Eloralintide is an investigational, long-acting, selective amylin receptor agonist developed by Lilly for once-weekly subcutaneous injection. It has no approved label.

What eloralintide doses were studied?

The 48-week phase 2 study used weekly 1, 3, 6 and 9 mg arms and two escalation arms, 6 to 9 mg and 3 to 9 mg. These were research assignments, not label doses.

How is eloralintide different from a GLP-1 medicine?

Eloralintide activates the amylin receptor, while GLP-1 medicines activate the GLP-1 receptor. Both are studied for weight management, through different hormone pathways.

Is eloralintide FDA approved?

No. Eloralintide is investigational. Its published human data come from phase 1 and phase 2 studies.

How long were the eloralintide studies?

The phase 1 multiple ascending dose study ran for 12 weeks and the phase 2 obesity study for 48 weeks. Both used once-weekly subcutaneous injections.

Where do these facts come from?

Sources are listed by kind: labels first, then peer-reviewed papers, then PinPoint's own library, arithmetic and app description. Library values were retrieved from the PinPoint application on 5 October 2026; vendor listings support package sizes only.

1. Eloralintide 48-week phase 2 obesity study, 2025The Lancet, 2025. Once-weekly 1, 3, 6 and 9 mg arms and two escalation arms; 263 participants.Retrieved 2026-10-05 · study
2. Eloralintide phase 1 multiple ascending dose study, 2026Diabetes Obes Metab, 2026. 12 weeks, once-weekly, no escalation; pharmacokinetics and tolerability.Retrieved 2026-10-05 · study
3. Eloralintide from discovery to clinical proof of concept, 2025Mol Metab, 2025. Discovery chemistry and early clinical data.Retrieved 2026-10-05 · study
4. PinPoint compound library, application recordsHalf-life inputs, routes, frequencies, package examples and confidence labels as stored in the iOS app library and mirrored in the peptide guides.Retrieved 2026-10-05 · library
5. Unit conversion arithmeticConcentration = amount / volume; volume = amount / concentration; U-100 units = mL x 100; remaining fraction = 2^(-elapsed / half-life).Retrieved 2026-10-05 · arithmetic
6. PinPoint App Store descriptionFeature wording from the approved application description, not pricing.Retrieved 2026-10-05 · app-description